HRP20090685T1 - Supstituirani derivati morfolina i tiomorfolina - Google Patents

Supstituirani derivati morfolina i tiomorfolina Download PDF

Info

Publication number: HRP20090685T1
Authority: HR; Croatia
Prior art keywords: phenyl; alk; morpholin; dimethyl; cycloalk
Prior art date: 2004-03-12

Application number

HR20090685T

Other languages

English (en)

Croatian (hr)

Inventor

Wenzel Tornoe Christian

Rottlnder Mario

Khanzhin Nikolay

Ritzen Andreas

Patrick Watson William

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-12

Filing date

2009-12-23

Publication date

2010-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37730781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090685(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-23 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2010-02-28 Publication of HRP20090685T1 publication Critical patent/HRP20090685T1/hr

Links

150000002780 morpholines Chemical class 0.000 title claims abstract 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title claims abstract 3
150000004886 thiomorpholines Chemical class 0.000 title claims abstract 3
229910052736 halogen Inorganic materials 0.000 claims abstract 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 9
150000002367 halogens Chemical class 0.000 claims abstract 8
125000004093 cyano group Chemical group *C#N 0.000 claims abstract 7
HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical class C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims abstract 6
125000004076 pyridyl group Chemical group 0.000 claims abstract 6
125000001424 substituent group Chemical group 0.000 claims abstract 6
125000005843 halogen group Chemical group 0.000 claims abstract 5
229910052717 sulfur Inorganic materials 0.000 claims abstract 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract 3
229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
239000001257 hydrogen Substances 0.000 claims abstract 3
125000001624 naphthyl group Chemical group 0.000 claims abstract 3
229910052760 oxygen Inorganic materials 0.000 claims abstract 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract 3
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract 3
150000003222 pyridines Chemical class 0.000 claims abstract 3
150000003839 salts Chemical class 0.000 claims abstract 3
229930192474 thiophene Natural products 0.000 claims abstract 3
150000003577 thiophenes Chemical class 0.000 claims abstract 3
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims abstract 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims abstract 2
239000012458 free base Substances 0.000 claims abstract 2
150000002240 furans Chemical class 0.000 claims abstract 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims abstract 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims abstract 2
150000002475 indoles Chemical class 0.000 claims abstract 2
150000002916 oxazoles Chemical class 0.000 claims abstract 2
150000003230 pyrimidines Chemical class 0.000 claims abstract 2
150000003233 pyrroles Chemical class 0.000 claims abstract 2
150000003248 quinolines Chemical class 0.000 claims abstract 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract 2
150000003557 thiazoles Chemical class 0.000 claims abstract 2
150000001875 compounds Chemical class 0.000 claims 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
208000019901 Anxiety disease Diseases 0.000 claims 9
201000010099 disease Diseases 0.000 claims 6
208000035475 disorder Diseases 0.000 claims 6
208000004296 neuralgia Diseases 0.000 claims 5
208000021722 neuropathic pain Diseases 0.000 claims 5
206010010904 Convulsion Diseases 0.000 claims 4
208000019695 Migraine disease Diseases 0.000 claims 3
206010027599 migraine Diseases 0.000 claims 3
208000015122 neurodegenerative disease Diseases 0.000 claims 3
PKOCZEXVIUDRRW-UHFFFAOYSA-N (2,6-dimethyl-4-morpholin-4-ylphenyl)carbamic acid Chemical compound CC1=C(NC(O)=O)C(C)=CC(N2CCOCC2)=C1 PKOCZEXVIUDRRW-UHFFFAOYSA-N 0.000 claims 2
208000008811 Agoraphobia Diseases 0.000 claims 2
208000004454 Hyperalgesia Diseases 0.000 claims 2
206010033664 Panic attack Diseases 0.000 claims 2
206010034912 Phobia Diseases 0.000 claims 2
206010036105 Polyneuropathy Diseases 0.000 claims 2
208000027520 Somatoform disease Diseases 0.000 claims 2
230000036506 anxiety Effects 0.000 claims 2
150000002148 esters Chemical class 0.000 claims 2
230000004770 neurodegeneration Effects 0.000 claims 2
208000027753 pain disease Diseases 0.000 claims 2
208000019906 panic disease Diseases 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
201000001716 specific phobia Diseases 0.000 claims 2
239000000126 substance Substances 0.000 claims 2
BKYHSCLAVOQZHZ-UHFFFAOYSA-N 2,6-dimethyl-4-morpholin-4-ylaniline Chemical compound CC1=C(N)C(C)=CC(N2CCOCC2)=C1 BKYHSCLAVOQZHZ-UHFFFAOYSA-N 0.000 claims 1
MBGBDCSGKYOPEA-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC=C1Cl MBGBDCSGKYOPEA-UHFFFAOYSA-N 0.000 claims 1
HQFQNYRKJOYWEY-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 HQFQNYRKJOYWEY-UHFFFAOYSA-N 0.000 claims 1
RDFIAPRCAVTVFL-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-(1,2-dimethyl-4-morpholin-4-ylcyclohexa-2,4-dien-1-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CCC1(C)NC(=O)CC1=CC=C(F)C(F)=C1 RDFIAPRCAVTVFL-UHFFFAOYSA-N 0.000 claims 1
LJUSTXRGYUENLJ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(F)C(F)=C1 LJUSTXRGYUENLJ-UHFFFAOYSA-N 0.000 claims 1
YYIRIYBLIVBHTF-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C(F)(F)F)=C1NC(=O)CC1=CC=C(F)C(F)=C1 YYIRIYBLIVBHTF-UHFFFAOYSA-N 0.000 claims 1
HJIGCVIPHPXEAG-UHFFFAOYSA-N 2-(3-bromophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(Br)=C1 HJIGCVIPHPXEAG-UHFFFAOYSA-N 0.000 claims 1
NBHOSDYTOKFPRM-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(Cl)=C1 NBHOSDYTOKFPRM-UHFFFAOYSA-N 0.000 claims 1
SUSVXXUDGGTLSU-UHFFFAOYSA-N 2-(3-fluorophenyl)-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(F)=C1 SUSVXXUDGGTLSU-UHFFFAOYSA-N 0.000 claims 1
NWZHLVIUDQICHI-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(Cl)C=C1 NWZHLVIUDQICHI-UHFFFAOYSA-N 0.000 claims 1
PSPKOXMCPHZZFA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[4-morpholin-4-yl-2-pyridin-3-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=C(C=2C=NC=CC=2)C=C(N2CCOCC2)C=C1C(F)(F)F PSPKOXMCPHZZFA-UHFFFAOYSA-N 0.000 claims 1
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
YDSRFTJYQRXZCE-UHFFFAOYSA-N 3,3-dimethyl-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]butanamide Chemical compound FC(F)(F)C1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 YDSRFTJYQRXZCE-UHFFFAOYSA-N 0.000 claims 1
XWLHXKMXYSTIJX-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)propanamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CCC1=CC=C(F)C(F)=C1 XWLHXKMXYSTIJX-UHFFFAOYSA-N 0.000 claims 1
XBLDZJXJCQTOHW-UHFFFAOYSA-N 3-(3-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)propanamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CCC1=CC=CC(Cl)=C1 XBLDZJXJCQTOHW-UHFFFAOYSA-N 0.000 claims 1
OGABBSFCFIJRPK-UHFFFAOYSA-N 5-methyl-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]hexanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CCCC(C)C)=C(C)C=C1N1CCOCC1 OGABBSFCFIJRPK-UHFFFAOYSA-N 0.000 claims 1
208000030507 AIDS Diseases 0.000 claims 1
206010001497 Agitation Diseases 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
208000020925 Bipolar disease Diseases 0.000 claims 1
241000589968 Borrelia Species 0.000 claims 1
208000014644 Brain disease Diseases 0.000 claims 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
206010013654 Drug abuse Diseases 0.000 claims 1
208000032274 Encephalopathy Diseases 0.000 claims 1
208000002877 Epileptic Syndromes Diseases 0.000 claims 1
208000011688 Generalised anxiety disease Diseases 0.000 claims 1
208000023105 Huntington disease Diseases 0.000 claims 1
208000035154 Hyperesthesia Diseases 0.000 claims 1
201000001916 Hypochondriasis Diseases 0.000 claims 1
208000016604 Lyme disease Diseases 0.000 claims 1
XFPRMSCCOJUEBM-UHFFFAOYSA-N N-[1-methyl-4-morpholin-4-yl-2-(trifluoromethyl)cyclohexa-2,4-dien-1-yl]hexanamide Chemical compound CC1(CC=C(C=C1C(F)(F)F)N1CCOCC1)NC(CCCCC)=O XFPRMSCCOJUEBM-UHFFFAOYSA-N 0.000 claims 1
206010029240 Neuritis Diseases 0.000 claims 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
206010052794 Panic disorder with agoraphobia Diseases 0.000 claims 1
206010033668 Panic disorder without agoraphobia Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
208000004983 Phantom Limb Diseases 0.000 claims 1
206010056238 Phantom pain Diseases 0.000 claims 1
102000004257 Potassium Channel Human genes 0.000 claims 1
241000710799 Rubella virus Species 0.000 claims 1
208000000810 Separation Anxiety Diseases 0.000 claims 1
206010041250 Social phobia Diseases 0.000 claims 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
231100000643 Substance intoxication Toxicity 0.000 claims 1
206010070863 Toxicity to various agents Diseases 0.000 claims 1
208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
206010048010 Withdrawal syndrome Diseases 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
230000001154 acute effect Effects 0.000 claims 1
208000012826 adjustment disease Diseases 0.000 claims 1
206010053552 allodynia Diseases 0.000 claims 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
CSWQFUWZYDMBLR-UHFFFAOYSA-N butyl n-(2,6-dimethyl-4-morpholin-4-ylphenyl)carbamate Chemical compound C1=C(C)C(NC(=O)OCCCC)=C(C)C=C1N1CCOCC1 CSWQFUWZYDMBLR-UHFFFAOYSA-N 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
230000036461 convulsion Effects 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
206010015037 epilepsy Diseases 0.000 claims 1
208000029364 generalized anxiety disease Diseases 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
208000015181 infectious disease Diseases 0.000 claims 1
208000014674 injury Diseases 0.000 claims 1
150000002500 ions Chemical class 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
LITBCMPJKSAOBQ-UHFFFAOYSA-N n-(1,2-dimethyl-4-morpholin-4-ylcyclohexa-2,4-dien-1-yl)-2-(3-methylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CCC1(C)NC(=O)CC1=CC=CC(C)=C1 LITBCMPJKSAOBQ-UHFFFAOYSA-N 0.000 claims 1
PCQHZOFRMZIDSO-UHFFFAOYSA-N n-(2,6-difluoro-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound C1=C(F)C(NC(=O)CC(C)(C)C)=C(F)C=C1N1CCOCC1 PCQHZOFRMZIDSO-UHFFFAOYSA-N 0.000 claims 1
BPFWCATXXHFMHU-UHFFFAOYSA-N n-(2,6-difluoro-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(F)C(NC(=O)CCCCC)=C(F)C=C1N1CCOCC1 BPFWCATXXHFMHU-UHFFFAOYSA-N 0.000 claims 1
FQXJKHBCIJGCQO-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 FQXJKHBCIJGCQO-UHFFFAOYSA-N 0.000 claims 1
WZSQCEVOMHBPFJ-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 WZSQCEVOMHBPFJ-UHFFFAOYSA-N 0.000 claims 1
DBQFAOANWIBIGE-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-naphthalen-2-ylacetamide Chemical compound C=1C(C)=C(NC(=O)CC=2C=C3C=CC=CC3=CC=2)C(C)=CC=1N1CCOCC1 DBQFAOANWIBIGE-UHFFFAOYSA-N 0.000 claims 1
IPQCETRADJWXPC-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-phenylacetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC=C1 IPQCETRADJWXPC-UHFFFAOYSA-N 0.000 claims 1
IQZIDXSIVOBHBG-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-thiophen-2-ylacetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CS1 IQZIDXSIVOBHBG-UHFFFAOYSA-N 0.000 claims 1
OVEJXWFUXCATFY-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 OVEJXWFUXCATFY-UHFFFAOYSA-N 0.000 claims 1
UULFYDWHIRAODG-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,5,5-trimethylhexanamide Chemical compound C1=C(C)C(NC(=O)CC(C)CC(C)(C)C)=C(C)C=C1N1CCOCC1 UULFYDWHIRAODG-UHFFFAOYSA-N 0.000 claims 1
CPXXAHUMOPUBQF-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3-ethylpentanamide Chemical compound C1=C(C)C(NC(=O)CC(CC)CC)=C(C)C=C1N1CCOCC1 CPXXAHUMOPUBQF-UHFFFAOYSA-N 0.000 claims 1
QDYMTVOPTQMLIP-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3-methylpentanamide Chemical compound C1=C(C)C(NC(=O)CC(C)CC)=C(C)C=C1N1CCOCC1 QDYMTVOPTQMLIP-UHFFFAOYSA-N 0.000 claims 1
TVSPKPCWJNRGPB-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-4-methylpentanamide Chemical compound C1=C(C)C(NC(=O)CCC(C)C)=C(C)C=C1N1CCOCC1 TVSPKPCWJNRGPB-UHFFFAOYSA-N 0.000 claims 1
FVUFQWDWZHWHQT-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-5-methylhexanamide Chemical compound C1=C(C)C(NC(=O)CCCC(C)C)=C(C)C=C1N1CCOCC1 FVUFQWDWZHWHQT-UHFFFAOYSA-N 0.000 claims 1
WZMQBLIZLSZDTE-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)heptanamide Chemical compound C1=C(C)C(NC(=O)CCCCCC)=C(C)C=C1N1CCOCC1 WZMQBLIZLSZDTE-UHFFFAOYSA-N 0.000 claims 1
RJPNBZXKFWESKX-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(C)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 RJPNBZXKFWESKX-UHFFFAOYSA-N 0.000 claims 1
ZYQZHRXKSVPLEG-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)octanamide Chemical compound C1=C(C)C(NC(=O)CCCCCCC)=C(C)C=C1N1CCOCC1 ZYQZHRXKSVPLEG-UHFFFAOYSA-N 0.000 claims 1
FLNIDPUBPDBGTL-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)pentanamide Chemical compound C1=C(C)C(NC(=O)CCCC)=C(C)C=C1N1CCOCC1 FLNIDPUBPDBGTL-UHFFFAOYSA-N 0.000 claims 1
CZXDPWCUNYIWRD-UHFFFAOYSA-N n-(2-chloro-6-methyl-4-morpholin-4-ylphenyl)-2-(3-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(Cl)=C1NC(=O)CC1=CC=CC(F)=C1 CZXDPWCUNYIWRD-UHFFFAOYSA-N 0.000 claims 1
BZNCUGFPSDUISB-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(OC)=CC(N2CCOCC2)=C1 BZNCUGFPSDUISB-UHFFFAOYSA-N 0.000 claims 1
KIEKLHLDPVXZRI-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)-4-methylpentanamide Chemical compound CC1=C(NC(=O)CCC(C)C)C(OC)=CC(N2CCOCC2)=C1 KIEKLHLDPVXZRI-UHFFFAOYSA-N 0.000 claims 1
LDGIJFPFNRCERN-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)-5-methylhexanamide Chemical compound CC1=C(NC(=O)CCCC(C)C)C(OC)=CC(N2CCOCC2)=C1 LDGIJFPFNRCERN-UHFFFAOYSA-N 0.000 claims 1
RUDPUVCWGIFSRS-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(OC)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 RUDPUVCWGIFSRS-UHFFFAOYSA-N 0.000 claims 1
JXVMTGLEBIWOHI-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2Br)N2CCOCC2)C(F)(F)F)=C1 JXVMTGLEBIWOHI-UHFFFAOYSA-N 0.000 claims 1
RMGDROBIXZIMJN-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=C(Br)C=C(N2CCOCC2)C=C1C(F)(F)F RMGDROBIXZIMJN-UHFFFAOYSA-N 0.000 claims 1
FPUGBBDCGLIOFN-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]butanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CCC)=C(Br)C=C1N1CCOCC1 FPUGBBDCGLIOFN-UHFFFAOYSA-N 0.000 claims 1
WOVDEFIGDUUBDM-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC)=C(Br)C=C1N1CCOCC1 WOVDEFIGDUUBDM-UHFFFAOYSA-N 0.000 claims 1
XSAPBUXDUGPCDB-UHFFFAOYSA-N n-[2-chloro-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2Cl)N2CCOCC2)C(F)(F)F)=C1 XSAPBUXDUGPCDB-UHFFFAOYSA-N 0.000 claims 1
ROGXWDNMPNMNEI-UHFFFAOYSA-N n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]hexanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 ROGXWDNMPNMNEI-UHFFFAOYSA-N 0.000 claims 1
125000004430 oxygen atom Chemical group O* 0.000 claims 1
244000052769 pathogen Species 0.000 claims 1
230000002093 peripheral effect Effects 0.000 claims 1
208000019629 polyneuritis Diseases 0.000 claims 1
230000007824 polyneuropathy Effects 0.000 claims 1
208000028173 post-traumatic stress disease Diseases 0.000 claims 1
108020001213 potassium channel Proteins 0.000 claims 1
208000020016 psychiatric disease Diseases 0.000 claims 1
208000025874 separation anxiety disease Diseases 0.000 claims 1
208000005809 status epilepticus Diseases 0.000 claims 1
208000011117 substance-related disease Diseases 0.000 claims 1
125000004434 sulfur atom Chemical group 0.000 claims 1
230000008733 trauma Effects 0.000 claims 1
206010044652 trigeminal neuralgia Diseases 0.000 claims 1
241001529453 unidentified herpesvirus Species 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

HR20090685T 2004-03-12 2009-12-23 Supstituirani derivati morfolina i tiomorfolina HRP20090685T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55257404P	2004-03-12	2004-03-12
DKPA200400412		2004-03-12

Publications (1)

Publication Number	Publication Date
HRP20090685T1 true HRP20090685T1 (hr)	2010-02-28

Family

ID=37730781

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20090685T HRP20090685T1 (hr)	2004-03-12	2009-12-23	Supstituirani derivati morfolina i tiomorfolina

Country Status (31)

Country	Link
US (6)	US7501414B2 (sr)
EP (3)	EP1727809B8 (sr)
JP (1)	JP5006184B2 (sr)
KR (2)	KR101411204B1 (sr)
CN (2)	CN102516204B (sr)
AR (1)	AR049784A1 (sr)
AT (2)	ATE398112T1 (sr)
AU (1)	AU2005221762B2 (sr)
BR (1)	BRPI0508570B8 (sr)
CA (1)	CA2559397C (sr)
CO (1)	CO5721001A2 (sr)
CY (2)	CY1110392T1 (sr)
DE (2)	DE602005007474D1 (sr)
DK (2)	DK1947093T3 (sr)
EA (1)	EA015120B1 (sr)
EG (1)	EG25344A (sr)
ES (2)	ES2306087T3 (sr)
HR (1)	HRP20090685T1 (sr)
IL (1)	IL177859A (sr)
MY (2)	MY143698A (sr)
NO (1)	NO337161B1 (sr)
NZ (1)	NZ549133A (sr)
PL (2)	PL1727809T3 (sr)
PT (2)	PT1727809E (sr)
RS (2)	RS50606B (sr)
SG (1)	SG151254A1 (sr)
SI (2)	SI1727809T1 (sr)
TW (2)	TWI349666B (sr)
UA (2)	UA102517C2 (sr)
WO (1)	WO2005087754A1 (sr)
ZA (2)	ZA200607286B (sr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050089559A1 (en)	2003-10-23	2005-04-28	Istvan Szelenyi	Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en)	2004-03-12	2011-10-01	Lundbeck & Co As H	Substituted morpholine and thiomorpholine derivatives
UA89503C2 (uk) *	2004-09-13	2010-02-10	Х. Луннбек А/С	Заміщені похідні аніліну
EP1861394A1 (en) *	2005-03-03	2007-12-05	H.Lundbeck A/S	Substituted pyridine derivatives
UA92340C2 (en) *	2005-03-03	2010-10-25	Х. Луннбек А/С	Substituted pyridine derivatives
TWI453013B (zh) *	2006-02-07	2014-09-21	Lundbeck & Co As H	N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
US7960436B2 (en)	2006-06-05	2011-06-14	Valeant Pharmaceuticals International	Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en)	2006-08-23	2015-03-31	Valeant Pharmaceuticals International	N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en)	2006-08-23	2011-09-29	Valeant Pharmaceuticals Int	Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
CN101578259A (zh)	2006-11-28	2009-11-11	威朗国际制药公司	作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
WO2008130616A2 (en) *	2007-04-19	2008-10-30	Schering Corporation	Diaryl morpholines as cb1 modulators
US8367684B2 (en)	2007-06-13	2013-02-05	Valeant Pharmaceuticals International	Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
AR070513A1 (es) *	2007-08-01	2010-04-14	Lundbeck & Co As H	Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
US7786146B2 (en)	2007-08-13	2010-08-31	Valeant Pharmaceuticals International	Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
SG157299A1 (en)	2008-05-09	2009-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
WO2010094644A1 (en) *	2009-02-17	2010-08-26	Neurosearch A/S	Substituted pyridine derivatives and their medical use
WO2010094645A1 (en) *	2009-02-17	2010-08-26	Neurosearch A/S	Substituted pyridine derivatives and their medical use
US20100286138A1 (en) *	2009-05-11	2010-11-11	H. Lundbeck A/S	Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
TW201041857A (en) *	2009-05-11	2010-12-01	Lundbeck & Co As H	Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20120232058A1 (en) *	2009-09-07	2012-09-13	Neurosearch A/S	Substituted pyridine derivatives and their medical use
AU2011275393B2 (en)	2010-07-08	2014-04-10	Pfizer Inc.	Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CN103073455B (zh)	2011-10-25	2015-08-19	中国科学院上海药物研究所	一类新型的kcnq钾通道激动剂、其制备方法和用途
EP2844247A4 (en) *	2012-04-20	2015-11-25	Anderson Gaweco	ROR MODULATORS AND ITS USES
CN103044431A (zh) *	2012-10-22	2013-04-17	中国药科大学	制备五氟磺草胺的新方法
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CA2969756A1 (en) *	2014-12-05	2016-06-09	Aquinnah Pharmaceuticals, Inc.	Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
EP3366683A1 (en) *	2017-02-28	2018-08-29	Acousia Therapeutics GmbH	Cyclic amides, acteamides and ureas useful as potassium channel openers
EP3917907B1 (en)	2019-01-29	2025-05-21	Universitá Degli Studi Di Salerno	Modulators of potassium ion channels and uses thereof
TWI886158B (zh)	2019-10-10	2025-06-11	加拿大商再諾製藥公司	選擇性鉀通道調節劑之固態晶型
MX2022005490A (es)	2019-11-08	2022-08-10	Xenon Pharmaceuticals Inc	Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en)	2021-02-09	2024-04-16	Xenon Pharmaceuticals Inc.	Methods and uses for treating anhedonia
IL282188A (en) *	2021-04-08	2022-11-01	Yeda Res & Dev	Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
CN116478068A (zh)	2022-01-14	2023-07-25	中国科学院上海药物研究所	一种高选择性kcnq4钾通道激动剂、其制备方法和用途
CN118239907B (zh) *	2024-03-25	2024-09-03	威海天宇新材料科技有限公司	一种橡胶硫化剂dtdm的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03175086A (ja) *	1989-09-14	1991-07-30	Fuji Photo Film Co Ltd	ジアゾ感熱記録材料
DE4200259A1 (de)	1992-01-08	1993-07-15	Asta Medica Ag	Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5688792A (en) *	1994-08-16	1997-11-18	Pharmacia & Upjohn Company	Substituted oxazine and thiazine oxazolidinone antimicrobials
DE19539861A1 (de)	1995-10-26	1997-04-30	Asta Medica Ag	Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
NZ329200A (en) *	1996-12-16	1999-05-28	Hoechst Ag	Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
AU730224B2 (en)	1996-12-23	2001-03-01	Du Pont Pharmaceuticals Company	Nitrogen containing heteroaromatics as factor Xa inhibitors
US6020357A (en) *	1996-12-23	2000-02-01	Dupont Pharmaceuticals Company	Nitrogen containing heteroaromatics as factor Xa inhibitors
DE69720773T2 (de) *	1996-12-23	2004-01-29	Bristol Myers Squibb Pharma Co	SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
US6187797B1 (en) *	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
EP1042299A1 (en)	1997-12-22	2000-10-11	Du Pont Pharmaceuticals Company	Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
CA2321538A1 (en)	1998-03-27	1999-10-07	Dupont Pharmaceuticals Company	Disubstituted pyrazolines and triazolines as factor xa inhibitors
EP1200086A4 (en) *	1999-08-04	2009-05-27	Icagen Inc	THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
US6495550B2 (en) *	1999-08-04	2002-12-17	Icagen, Inc.	Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en)	1999-09-27	2000-09-12	Asta Medica Aktiengesellschaft	Use of retigabine for the treatment of neuropathic pain
WO2001092526A1 (en)	2000-05-26	2001-12-06	Bristol-Myers Squibb Company	Human kcnq5 potassium channel, methods and compositions thereof
WO2001096540A2 (en)	2000-06-11	2001-12-20	Dupont Pharmaceuticals Company	Hepatitis c protease exosite for inhibitor design
PE20020044A1 (es) *	2000-06-16	2002-01-30	Upjohn Co	Tiazina oxazolidinona
US6589986B2 (en)	2000-12-20	2003-07-08	Wyeth	Methods of treating anxiety disorders
JP2004517129A (ja) *	2001-01-16	2004-06-10	アストラゼネカ・アクチエボラーグ	治療用クロモン化合物
NZ526699A (en) *	2001-01-16	2005-03-24	Astrazeneca Ab	8-amino derivatives and their use in treating migraine
CN1250519C (zh) *	2001-01-19	2006-04-12	中国人民解放军军事医学科学院毒物药物研究所	具有调节钾通道功能的胺衍生物及其制备方法和应用
CZ20032233A3 (cs)	2001-02-20	2004-12-15	Bristol-Myers Squibb Company	Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
SE0103648D0 (sv) *	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinolone compounds
SE0103649D0 (sv) *	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
TWI349666B (en)	2004-03-12	2011-10-01	Lundbeck & Co As H	Substituted morpholine and thiomorpholine derivatives

2005
- 2005-03-03 TW TW094106488A patent/TWI349666B/zh not_active IP Right Cessation
- 2005-03-03 TW TW096141845A patent/TWI357901B/zh not_active IP Right Cessation
- 2005-03-08 AR ARP050100893A patent/AR049784A1/es active IP Right Grant
- 2005-03-09 JP JP2007502191A patent/JP5006184B2/ja not_active Expired - Fee Related
- 2005-03-09 PL PL05706819T patent/PL1727809T3/pl unknown
- 2005-03-09 SI SI200530344T patent/SI1727809T1/sl unknown
- 2005-03-09 PL PL08007169T patent/PL1947093T3/pl unknown
- 2005-03-09 PT PT05706819T patent/PT1727809E/pt unknown
- 2005-03-09 DK DK08007169.9T patent/DK1947093T3/da active
- 2005-03-09 EA EA200601686A patent/EA015120B1/ru unknown
- 2005-03-09 SG SG200901657-7A patent/SG151254A1/en unknown
- 2005-03-09 KR KR1020067018688A patent/KR101411204B1/ko not_active Expired - Fee Related
- 2005-03-09 EP EP05706819A patent/EP1727809B8/en not_active Expired - Lifetime
- 2005-03-09 AT AT05706819T patent/ATE398112T1/de active
- 2005-03-09 KR KR1020127029156A patent/KR20120136422A/ko not_active Ceased
- 2005-03-09 CN CN201110328836.0A patent/CN102516204B/zh not_active Expired - Fee Related
- 2005-03-09 RS RSP-2008/0412A patent/RS50606B/sr unknown
- 2005-03-09 ES ES05706819T patent/ES2306087T3/es not_active Expired - Lifetime
- 2005-03-09 AU AU2005221762A patent/AU2005221762B2/en not_active Ceased
- 2005-03-09 RS RSP-2009/0558A patent/RS51066B/sr unknown
- 2005-03-09 WO PCT/DK2005/000159 patent/WO2005087754A1/en not_active Ceased
- 2005-03-09 EP EP09170831A patent/EP2138487A1/en not_active Withdrawn
- 2005-03-09 PT PT08007169T patent/PT1947093E/pt unknown
- 2005-03-09 DE DE602005007474T patent/DE602005007474D1/de not_active Expired - Lifetime
- 2005-03-09 CN CNA2005800078857A patent/CN1930138A/zh active Pending
- 2005-03-09 ES ES08007169T patent/ES2334076T3/es not_active Expired - Lifetime
- 2005-03-09 EP EP08007169A patent/EP1947093B9/en not_active Expired - Lifetime
- 2005-03-09 DE DE602005016849T patent/DE602005016849D1/de not_active Expired - Lifetime
- 2005-03-09 NZ NZ549133A patent/NZ549133A/en not_active IP Right Cessation
- 2005-03-09 BR BRPI0508570A patent/BRPI0508570B8/pt not_active IP Right Cessation
- 2005-03-09 CA CA2559397A patent/CA2559397C/en not_active Expired - Lifetime
- 2005-03-09 AT AT08007169T patent/ATE443702T1/de active
- 2005-03-09 UA UAA200911734A patent/UA102517C2/ru unknown
- 2005-03-09 SI SI200530872T patent/SI1947093T1/sl unknown
- 2005-03-09 DK DK05706819T patent/DK1727809T3/da active
- 2005-03-11 MY MYPI20051046A patent/MY143698A/en unknown
- 2005-03-11 MY MYPI20094719A patent/MY147786A/en unknown
- 2005-09-03 UA UAA200610517A patent/UA90670C2/uk unknown
- 2005-12-21 US US11/314,802 patent/US7501414B2/en not_active Expired - Lifetime
2006
- 2006-08-31 ZA ZA2006/07286A patent/ZA200607286B/en unknown
- 2006-09-03 IL IL177859A patent/IL177859A/en active IP Right Grant
- 2006-09-12 EG EGNA2006000856 patent/EG25344A/xx active
- 2006-09-12 CO CO06091597A patent/CO5721001A2/es active IP Right Grant
- 2006-10-10 NO NO20064599A patent/NO337161B1/no not_active IP Right Cessation
2007
- 2007-11-12 ZA ZA200709718A patent/ZA200709718B/xx unknown
2008
- 2008-09-10 CY CY20081100969T patent/CY1110392T1/el unknown
2009
- 2009-01-28 US US12/361,509 patent/US7632835B2/en not_active Expired - Fee Related
- 2009-01-28 US US12/361,404 patent/US20090143369A1/en not_active Abandoned
- 2009-11-03 US US12/611,249 patent/US8012962B2/en not_active Expired - Fee Related
- 2009-11-05 US US12/612,727 patent/US7812023B2/en not_active Expired - Lifetime
- 2009-12-21 CY CY20091101325T patent/CY1109656T1/el unknown
- 2009-12-23 HR HR20090685T patent/HRP20090685T1/hr unknown
2011
- 2011-07-28 US US13/192,833 patent/US8299075B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BRPI0508570A (pt)	2007-08-14
US8299075B2 (en)	2012-10-30
US20100063033A1 (en)	2010-03-11
US7812023B2 (en)	2010-10-12
PT1947093E (pt)	2009-12-22
US20100063036A1 (en)	2010-03-11
NO20064599L (no)	2006-12-08
TWI349666B (en)	2011-10-01
BRPI0508570B1 (pt)	2018-11-21
CN102516204A (zh)	2012-06-27
US20060167248A1 (en)	2006-07-27
CO5721001A2 (es)	2007-01-31
AU2005221762A1 (en)	2005-09-22
UA90670C2 (en)	2010-05-25
HK1172618A1 (zh)	2013-04-26
SI1727809T1 (sl)	2008-10-31
AR049784A1 (es)	2006-09-06
KR20060128004A (ko)	2006-12-13
EP2138487A1 (en)	2009-12-30
MY143698A (en)	2011-06-30
DK1727809T3 (da)	2008-09-29
IL177859A0 (en)	2006-12-31
US20090137571A1 (en)	2009-05-28
EP1727809A1 (en)	2006-12-06
PT1727809E (pt)	2008-08-13
EA200601686A1 (ru)	2007-02-27
DE602005007474D1 (en)	2008-07-24
ES2334076T3 (es)	2010-03-04
EP1947093A1 (en)	2008-07-23
US7501414B2 (en)	2009-03-10
DE602005016849D1 (de)	2009-11-05
KR101411204B1 (ko)	2014-06-23
US20090143369A1 (en)	2009-06-04
NO337161B1 (no)	2016-02-01
SG151254A1 (en)	2009-04-30
KR20120136422A (ko)	2012-12-18
UA102517C2 (ru)	2013-07-25
US8012962B2 (en)	2011-09-06
BRPI0508570B8 (pt)	2021-05-25
EP1947093B9 (en)	2010-03-03
CA2559397C (en)	2010-08-10
ZA200709718B (en)	2008-09-25
US20110294787A1 (en)	2011-12-01
EA015120B1 (ru)	2011-06-30
ES2306087T3 (es)	2008-11-01
DK1947093T3 (da)	2010-02-01
PL1727809T3 (pl)	2008-11-28
IL177859A (en)	2013-02-28
SI1947093T1 (sl)	2010-01-29
JP2007528880A (ja)	2007-10-18
TW200811121A (en)	2008-03-01
AU2005221762B2 (en)	2011-06-09
EP1727809B8 (en)	2008-10-29
ZA200607286B (en)	2008-04-30
MY147786A (en)	2013-01-31
ATE443702T1 (de)	2009-10-15
NZ549133A (en)	2010-09-30
CY1109656T1 (el)	2014-08-13
CA2559397A1 (en)	2005-09-22
TWI357901B (en)	2012-02-11
TW200533359A (en)	2005-10-16
JP5006184B2 (ja)	2012-08-22
CN1930138A (zh)	2007-03-14
CN102516204B (zh)	2016-01-20
RS50606B (sr)	2010-05-07
CY1110392T1 (el)	2015-04-29
EP1727809B1 (en)	2008-06-11
US7632835B2 (en)	2009-12-15
WO2005087754A1 (en)	2005-09-22
RS51066B (sr)	2010-10-31
EP1947093B1 (en)	2009-09-23
ATE398112T1 (de)	2008-07-15
PL1947093T3 (pl)	2010-02-26
EG25344A (en)	2011-12-14

Publication	Publication Date	Title
HRP20090685T1 (hr)	2010-02-28	Supstituirani derivati morfolina i tiomorfolina
NZ573832A (en)	2011-11-25	N-(4-{ 2-[4-aryl-piperazin-1-yl]ethyl} cyclohexyl)-acetamide derivatives for the treatment of neuropsychiatric disorders
CA2599890A1 (en)	2006-09-08	Substituted pyridine derivatives
CR20230586A (es)	2024-05-07	N-(hydroxyalquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
DK1682138T3 (da)	2011-04-18	Heterocykliske inhibitorer af MEK
CA2732806A1 (en)	2010-02-11	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY156747A (en)	2016-03-31	Isoxazolo-pyridine derivatives
RU2356893C2 (ru)	2009-05-27	Ингибиторы фосфодиэстеразы 4
EA200500304A1 (ru)	2005-10-27	Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
NO20055316L (no)	2006-01-11	Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike
CA2593264A1 (en)	2006-07-27	Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
NO20084350L (no)	2008-10-16	Heterocykliske amider til anvendelse som farmasoytika
RU2010119554A (ru)	2011-11-27	Замещенные n-фенил-бипирролидинмочевины и их терапевтическое применение
WO2007071632A3 (en)	2007-08-30	2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
NO20090979L (no)	2009-05-06	(3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
DK1556354T3 (da)	2008-06-02	Terapeutiske piperazinderivater, der er egnede til behandling af smerter
ATE522526T1 (de)	2011-09-15	4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
ECSP055644A (es)	2005-07-06	Derivados de la quinolil-propil-piperidina y su utilización
HRP20120876T1 (hr)	2012-11-30	Brzo disocirajuä†i antagonisti dopamin 2 receptora
MX2009013119A (es)	2010-03-04	Derivados de 2-[2-(fenil)etilamino]alcanamida sustituidos y su uso como moduladores del canal de sodio y/o potasio.
CA2570197A1 (en)	2006-01-19	Nk1 antagonists
HRP20150569T1 (hr)	2015-07-03	5-(fenil/piridinil-etinil)-2-piridin/2-pirimidin-karboksamidi kao modulatori za mglur5
NZ597498A (en)	2013-06-28	Cyclopropyl amine derivatives as histamin H3 receptor modulators
HRP20120913T1 (hr)	2012-12-31	Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora
ATE406894T1 (de)	2008-09-15	4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer